Ultragenyx sold 2 PRVs for $203M and $210M; Biomea's BMF-650 showed modest weight loss; Skyhook Bio shutters; Altay raises ...
Arrowhead Pharmaceuticals' ARO-MAPT subcutaneous injection reduced tau protein by up to 85% in healthy volunteers, ...
Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes ...
GSK will make up to 1,217 workers redundant from its sites in Belgium as part of the cost-cutting initiative CEO Luke Miels ...
Beam Therapeutics shared Phase 1/2 data on BEAM-301 for GSDIa; Pfizer partnered with Enodia on Sec61 inhibitors for $500M+; ...
Soufflé Therapeutics raises a $135M Series B led by Juvia Group to push siRNA drugs for FSHD and heart failure into the clinic.
Heidi, an Australian AI health startup, raised $340M from General Catalyst to pursue FDA approval for AI-driven prescribing ...
For decades, Rudy Tanzi has dreamt of a 'little white pill' to prevent Alzheimer’s disease that would be so cheap and so safe ...
Brent Saunders exits as Bausch + Lomb CEO by mutual agreement, replaced interim by Thomas Appio. Shares down 3%. Company to ...
Mirum's Livmarli, First Tracks' ANB033, and Tortugas' obuprazine showed positive Phase 3, 1b, and 2b trial results in liver ...
BioNTech’s mRNA vaccine BNT113 misses PFS goal in a Phase 2/3 head and neck cancer trial; the study continues toward its overall survival endpoint.
A trial testing admilparant in IPF succeeded at the lower 60 mg dose, while the higher 120 mg dose failed. And the GEP-NET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results